Group 1 - Ave Maria Growth Fund reported a return of -0.48% in Q3 2025, underperforming the S&P 500 Index which returned 8.12% and the S&P 500® Dividend Aristocrats Index which returned 2.97% [1] - The fund highlighted AptarGroup, Inc. (NYSE:ATR) as a key investment, noting its strong position in drug delivery solutions and dispensing technologies [2][3] - AptarGroup, Inc. has a market capitalization of $7.943 billion, with its stock closing at $120.56 per share on January 6, 2026 [2] Group 2 - AptarGroup, Inc. experienced a one-month return of 2.89%, but its shares have declined by 21.79% over the last 52 weeks [2] - The management of AptarGroup indicated several near-term challenges, but the fund believes these issues are transitory and that the stock is undervalued for long-term investors [3] - Despite its potential, AptarGroup is not among the 30 most popular stocks among hedge funds, with 29 hedge fund portfolios holding its stock at the end of Q3 2025 [4]